HPV vaccination after treatment for cervical dysplasia
The Role of Adjuvant VaccInation After Conization for the Treatment for Cervical Dysplasia
This study tests whether getting the HPV vaccine after treatment for cervical dysplasia can help prevent the return of HPV-related issues in women.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Academic / other |
| Locations | 2 sites (Milan, Lombardy and 1 other locations) |
| Trial ID | NCT06611020 on ClinicalTrials.gov |
What this trial studies
This study evaluates the potential protective role of HPV vaccination in women who have undergone treatment for HPV-related cervical lesions. Participants will be counseled about the benefits of vaccination and monitored for the risk of HPV recurrence. The study compares outcomes between those who choose to receive the vaccine and those who do not. It aims to gather data on the effectiveness of vaccination in preventing recurrence after excisional treatment.
Who should consider this trial
Good fit: Ideal candidates are women who have been treated for HPV-related cervical lesions but have not previously received HPV vaccination.
Not a fit: Patients who have already been vaccinated against HPV will not benefit from this study.
Why it matters
Potential benefit: If successful, this could significantly reduce the risk of HPV recurrence in women treated for cervical dysplasia.
How similar studies have performed: While there is limited data on this specific approach, previous studies have suggested that HPV vaccination can reduce recurrence rates in similar contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Treatment of HPV-related disease Exclusion Criteria: * Previous HPV vaccination
Where this trial is running
Milan, Lombardy and 1 other locations
- Fondazione IRCCS Istituto Nazionale dei Tumori — Milan, Lombardy, Italy (Recruiting)
- Fondazione IRCCS Istituto Nazionale dei Tumori — Milan, Lombardy, Italy (Recruiting)
Study contacts
- Principal investigator: Grazia Casadei, MD — Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Study coordinator: Giorgio Bogani, ph.d.
- Email: giorgiobogani@yahoo.it
- Phone: 651-296-9676
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.